DB:WEK

Stock Analysis Report

Executive Summary

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens.

Rewards

PE ratio (5.5x) is below the German market (21.1x)

Earnings are forecast to grow 36.3% per year

Became profitable this year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Highly volatile share price over past 3 months

Shareholders have been diluted in the past year



Snowflake Analysis

Flawless balance sheet and fair value.


Similar Companies

Share Price & News

How has ZIOPHARM Oncology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: WEK's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

5.1%

WEK

1.0%

DE Biotechs

2.0%

DE Market


1 Year Return

28.3%

WEK

6.8%

DE Biotechs

15.1%

DE Market

Return vs Industry: WEK exceeded the German Biotechs industry which returned 6.2% over the past year.

Return vs Market: WEK exceeded the German Market which returned 15% over the past year.


Shareholder returns

WEKIndustryMarket
7 Day5.1%1.0%2.0%
30 Day-31.6%-1.2%1.0%
90 Day-27.5%7.4%3.8%
1 Year28.3%28.3%7.1%6.8%18.6%15.1%
3 Year-54.3%-54.3%48.3%46.6%16.8%6.6%
5 Year-68.6%-68.6%11.4%9.0%23.7%6.7%

Price Volatility Vs. Market

How volatile is ZIOPHARM Oncology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ZIOPHARM Oncology undervalued compared to its fair value and its price relative to the market?

5.53x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate WEK's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate WEK's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: WEK is good value based on its PE Ratio (5.5x) compared to the Biotechs industry average (43.8x).

PE vs Market: WEK is good value based on its PE Ratio (5.5x) compared to the German market (21.1x).


Price to Earnings Growth Ratio

PEG Ratio: WEK is good value based on its PEG Ratio (0.2x)


Price to Book Ratio

PB vs Industry: WEK is overvalued based on its PB Ratio (5.4x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is ZIOPHARM Oncology forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

36.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: WEK's forecast earnings growth (36.3% per year) is above the savings rate (-0.4%).

Earnings vs Market: WEK's earnings (36.3% per year) are forecast to grow faster than the German market (13.3% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: WEK is forecast to have no revenue next year.

High Growth Revenue: WEK is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if WEK's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has ZIOPHARM Oncology performed over the past 5 years?

37.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: WEK has high quality earnings.

Growing Profit Margin: WEK became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: WEK has become profitable over the past 5 years, growing earnings by 37.2% per year.

Accelerating Growth: WEK has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: WEK has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: WEK's Return on Equity (-107.9%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is ZIOPHARM Oncology's financial position?


Financial Position Analysis

Short Term Liabilities: WEK's short term assets ($115.6M) exceed its short term liabilities ($11.2M).

Long Term Liabilities: WEK's short term assets ($115.6M) exceed its long term liabilities ($647.0K).


Debt to Equity History and Analysis

Debt Level: WEK is debt free.

Reducing Debt: WEK has not had any debt for past 5 years.


Balance Sheet

Inventory Level: WEK has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if WEK's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: WEK is profitable, therefore cash runway is not a concern.

Forecast Cash Runway: WEK is profitable, therefore cash runway is not a concern.


Next Steps

Dividend

What is ZIOPHARM Oncology's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate WEK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate WEK's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if WEK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if WEK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of WEK's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Laurence James Cooper (54yo)

4.8yrs

Tenure

US$1,589,239

Compensation

Dr. Laurence James Neil Cooper, M.D., Ph.D., has been a Director of Ziopharm Oncology, Inc since October 15, 2018. Dr. Cooper has been the Chief Executive Officer of ZIOPHARM Oncology, Inc. since May 5, 20 ...


CEO Compensation Analysis

Compensation vs Market: Laurence James's total compensation ($USD1.59M) is above average for companies of similar size in the German market ($USD1.15M).

Compensation vs Earnings: Laurence James's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Laurence James Cooper
CEO & Director4.8yrsUS$1.59m0.92% $5.6m
David Mauney
President1.2yrsUS$608.76k0.13% $809.4k
Robert Hadfield
Executive VP0yrsUS$836.09k0.077% $469.1k
Satyavrat Shukla
Executive VP & CFO0.6yrsno data0.039% $236.3k
Lynn Ferrucci
Executive VP of HR0yrsno datano data
Christopher Taylor
Vice President of Investor Relations & Corporate Communications0yrsno datano data
Jill Buck
Executive Vice President of GM Gene Therapy1.3yrsno data0.11% $667.5k
Eleanor De Groot
Executive Vice President of GM Cell Therapy0.9yrsno data0.11% $669.3k
Drew Deniger
Head of TCR-T Cell Therapy Program0.6yrsno datano data

1.0yrs

Average Tenure

48.5yo

Average Age

Experienced Management: WEK's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Laurence James Cooper
CEO & Director4.8yrsUS$1.59m0.92% $5.6m
Scott Tarriff
Chairman0.8yrsUS$212.58k0.045% $276.5k
George Demetri
Member of Scientific/Medical Advisory Board0yrsno datano data
James Armitage
Member of Scientific/Medical Advisory Board0yrsno datano data
Joseph Bertino
Member of Scientific/Medical Advisory Board0yrsno datano data
Lawrence Einhorn
Member of Scientific/Medical Advisory Board0yrsno datano data
Alan Houghton
Member of Scientific/Medical Advisory Board0yrsno datano data
Alberto Pappo
Member of Scientific/Medical Advisory Board0yrsno datano data
John Smyth
Member of Scientific/Medical Advisory Board13.1yrsno datano data
Douglas Pagán
Independent Director5.2yrsUS$274.23k0.017% $105.5k

3.3yrs

Average Tenure

59yo

Average Age

Experienced Board: WEK's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.1%.


Top Shareholders

Company Information

ZIOPHARM Oncology, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ZIOPHARM Oncology, Inc.
  • Ticker: WEK
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$659.171m
  • Listing Market Cap: US$608.415m
  • Shares outstanding: 207.29m
  • Website: https://www.ziopharm.com

Number of Employees


Location

  • ZIOPHARM Oncology, Inc.
  • Parris Building 34
  • Navy Yard Plaza
  • Boston
  • Massachusetts
  • 2129
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ZIOPNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDSep 2005
WEKDB (Deutsche Boerse AG)YesCommon StockDEEURSep 2005

Biography

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient’s immune system to attack cancer cells. Its lead gene therapy product candidate is Ad-RTS-hIL-12 plus veledimex, which is in Phase I clinical trial, to treat patients with recurrent glioblastoma and breast cancer. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; research and development agreement with the National Cancer Institute, and Ares Trading S.A. The company is headquartered in Boston, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/17 21:07
End of Day Share Price2020/02/17 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.